Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety
- PMID: 20473055
- DOI: 10.1097/JCP.0b013e3181dac52f
Prazosin versus quetiapine for nighttime posttraumatic stress disorder symptoms in veterans: an assessment of long-term comparative effectiveness and safety
Abstract
Posttraumatic stress disorder (PTSD) is an anxiety disorder experienced by combat veterans. Nighttime symptoms are often unrelieved by selective serotonin reuptake inhibitor therapy, and increased use of prazosin or quetiapine for treatment is seen. The purpose of this study was to determine the short- and long-term effectiveness and safety of prazosin versus quetiapine for treating nighttime symptoms in veteran PTSD patients. This is a historical prospective cohort study using retrospective chart review. Three hundred twenty-four patients with a diagnosis of PTSD, based on International Classification of Diseases, Ninth Revision coding, who were initially prescribed prazosin or quetiapine for nighttime symptoms were screened for inclusion. Short-term effectiveness was determined by documentation of symptomatic improvement within 6 months, and long-term effectiveness if patients continued therapy to study end date. Safety was assessed by comparing incidence of adverse drug effects causing discontinuation of either study drug. This study included 237 patients: 62 received prazosin, and 175 received quetiapine. Short-term effectiveness was similar for prazosin (61.3%) and quetiapine (61.7%; P = 0.54). However, patients prescribed prazosin were significantly more likely to continue their therapy to study end date compared with quetiapine (48.4% vs 24%; P < 0.001; odds ratio, 3.0; 95% confidence interval, 1.62-5.45), thus achieving long-term effectiveness. Alternatively, patients in the quetiapine group were more likely to discontinue therapy because of adverse effects compared with the prazosin group (34.9% vs 17.7%; P = 0.008). Because of similar rate of short-term effectiveness, superior long-term effectiveness, and lower incidence of events leading to discontinuation, compared with quetiapine, prazosin should be used first-line for treating nighttime PTSD symptoms in a veteran population.
Similar articles
-
Tracing the flow of knowledge: geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs.Arch Gen Psychiatry. 2009 Apr;66(4):417-21. doi: 10.1001/archgenpsychiatry.2008.536. Arch Gen Psychiatry. 2009. PMID: 19349311
-
A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder.Biol Psychiatry. 2007 Apr 15;61(8):928-34. doi: 10.1016/j.biopsych.2006.06.032. Epub 2006 Oct 25. Biol Psychiatry. 2007. PMID: 17069768 Clinical Trial.
-
Medication adherence and its effect on relapse among patients discharged from a Veterans Affairs posttraumatic stress disorder treatment program.Ann Pharmacother. 2009 Jul;43(7):1227-32. doi: 10.1345/aph.1M017. Epub 2009 Jul 7. Ann Pharmacother. 2009. PMID: 19584387
-
Prazosin for the treatment of posttraumatic stress disorder sleep disturbances.Pharmacotherapy. 2008 May;28(5):656-66. doi: 10.1592/phco.28.5.656. Pharmacotherapy. 2008. PMID: 18447662 Review.
-
The efficacy of prazosin for the treatment of posttraumatic stress disorder nightmares in U.S. military veterans.J Am Assoc Nurse Pract. 2017 Feb;29(2):65-69. doi: 10.1002/2327-6924.12432. Epub 2016 Dec 15. J Am Assoc Nurse Pract. 2017. PMID: 27977074 Review.
Cited by
-
Pharmacotherapy of 1,044 inpatients with posttraumatic stress disorder: current status and trends in German-speaking countries.Eur Arch Psychiatry Clin Neurosci. 2021 Sep;271(6):1065-1076. doi: 10.1007/s00406-020-01223-x. Epub 2020 Dec 28. Eur Arch Psychiatry Clin Neurosci. 2021. PMID: 33369692 Free PMC article.
-
Quetiapine Treatment for Post-traumatic Stress Disorder: A Systematic Review of the Literature.Clin Psychopharmacol Neurosci. 2023 Feb 28;21(1):49-56. doi: 10.9758/cpn.2023.21.1.49. Clin Psychopharmacol Neurosci. 2023. PMID: 36700311 Free PMC article. Review.
-
Targeting memory processes with drugs to prevent or cure PTSD.Expert Opin Investig Drugs. 2012 Sep;21(9):1323-50. doi: 10.1517/13543784.2012.704020. Epub 2012 Jul 27. Expert Opin Investig Drugs. 2012. PMID: 22834476 Free PMC article. Review.
-
Untangling PTSD and TBI: Challenges and Strategies in Clinical Care and Research.Curr Neurol Neurosci Rep. 2018 Nov 8;18(12):106. doi: 10.1007/s11910-018-0908-5. Curr Neurol Neurosci Rep. 2018. PMID: 30406855 Review.
-
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.BMC Psychiatry. 2014;14 Suppl 1(Suppl 1):S1. doi: 10.1186/1471-244X-14-S1-S1. Epub 2014 Jul 2. BMC Psychiatry. 2014. PMID: 25081580 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical